Free and open · new CVEs checked every 20 minutesStatusRSSOpen dataContact

CVE-2025-40834: A vulnerability has been identified in Mendix RichText (All versions >= V4.0.0 < V4.6.1)

24
Routine
MEDIUM 5.7

CVE-2025-40834 is a medium-severity flaw (CVSS 5.7) affecting affected software. Below: why it ranks where it does, which versions are affected, what to do, and the exact commands.

A vulnerability has been identified in Mendix RichText (All versions >= V4.0.0 < V4.6.1). Affected widget does not properly neutralize the input. This could allow an attacker to execute cross-site scripting attacks.

Why this priority

  • No elevated risk signals yet

No fix is published yet: follow the downgrade or mitigation steps.

Risk facts

CVSS score5.7 (Medium)
Attack vectorNetwork (remote)
Attack complexityLow
Privileges neededLow
User interactionRequired
EPSS exploit chance0.3% (top 84%)
CISA exploited listNo
WeaknessCWE-79
Published2025-11-17
Last modified2026-10-23
Publisher (CNA): Siemens AG

Last updated 2026-10-23 · Sources: CVE Program, NVD, CISA KEV, EPSS and vendor advisories · How we score

Timeline

Verify at the official source NVD · CVE Program · Report a problem with this page
Scores and fixes here are computed automatically from those and other public sources. Confirm with the vendor advisory before changing production systems.

Quick answers

How do I fix CVE-2025-40834?

No fixed release is listed yet. Watch the vendor advisory and apply any mitigation shown on this page.

Is CVE-2025-40834 being exploited?

CVE-2025-40834 is not on the CISA Known Exploited Vulnerabilities list at the time of the last update. Check again, as this can change.

What does CVE-2025-40834 affect?

CVE-2025-40834 affects affected software. Severity is medium (CVSS 5.7). A vulnerability has been identified in Mendix RichText (All versions >= V4.0.0 < V4.6.1). Affected widget does not properly neutralize the input. This could allow an attacker to execute cross-site scripting attacks.

How urgent is CVE-2025-40834?

Priority 24/100. No elevated risk signals yet.

References

← Back to latest CVEs